

# Camilla Krakstad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2478428/publications.pdf>

Version: 2024-02-01

134  
papers

5,795  
citations

109137

35  
h-index

88477

70  
g-index

139  
all docs

139  
docs citations

139  
times ranked

10865  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , 2014, 506, 371-375.  | 13.7 | 708       |
| 2  | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.                                     | 9.4  | 493       |
| 3  | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.   | 9.4  | 326       |
| 4  | Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. <i>Molecular Cancer</i> , 2010, 9, 135.   | 7.9  | 247       |
| 5  | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.   | 9.4  | 221       |
| 6  | Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.  | 5.8  | 178       |
| 7  | cAMP effector mechanisms. Novel twists for an $\text{A}^{\sim}\text{old}^{\text{TM}}$ signaling system. <i>FEBS Letters</i> , 2003, 546, 121-126.   | 1.3  | 174       |
| 8  | The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. <i>Nature Genetics</i> , 2016, 48, 848-855.   | 9.4  | 174       |
| 9  | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.  | 5.8  | 144       |
| 10 | Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. <i>European Journal of Cancer</i> , 2013, 49, 3431-3441.         | 1.3  | 123       |
| 11 | Lack of Estrogen Receptor- $\beta$ Is Associated with Epithelial $\rightarrow$ Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 1094-1105. | 3.2  | 120       |
| 12 | Ca <sup>2+</sup> /Calmodulin-dependent Protein Kinase II Is Required for Microcystin-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2002, 277, 2804-2811.                                      | 1.6  | 106       |
| 13 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.   | 5.8  | 98        |
| 14 | Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1637-1647.                       | 1.9  | 91        |
| 15 | Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , 2014, 13, 223.   | 7.9  | 88        |
| 16 | Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. <i>European Journal of Cancer</i> , 2014, 50, 3003-3010.                     | 1.3  | 73        |
| 17 | Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. <i>PLoS ONE</i> , 2013, 8, e54873.                                     | 1.1  | 70        |
| 18 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.   | 5.8  | 63        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018, 7, 1978-1987.   | 1.3 | 62        |
| 20 | ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. <i>Modern Pathology</i> , 2013, 26, 428-434.  | 2.9 | 61        |
| 21 | Loss of GPER identifies new targets for therapy among a subgroup of ER $\pm$ -positive endometrial cancer patients with poor outcome. <i>British Journal of Cancer</i> , 2012, 106, 1682-1688.   | 2.9 | 54        |
| 22 | Androgen receptor as potential therapeutic target in metastatic endometrial cancer. <i>Oncotarget</i> , 2016, 7, 49289-49298.  | 0.8 | 53        |
| 23 | Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer &amp; Metabolism</i> , 2019, 7, 6.                                     | 2.4 | 51        |
| 24 | Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. <i>Oncotarget</i> , 2015, 6, 1327-1339.                                 | 0.8 | 50        |
| 25 | Risk of Ovarian Cancer and the NF- $\kappa$ B Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . <i>Cancer Research</i> , 2014, 74, 852-861.   | 0.4 | 48        |
| 26 | PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. <i>Molecular Oncology</i> , 2015, 9, 1694-1703.  | 2.1 | 47        |
| 27 | Whole-Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 928-937.  | 1.9 | 47        |
| 28 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.   | 1.1 | 44        |
| 29 | HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. <i>British Journal of Cancer</i> , 2018, 118, 378-387.   | 2.9 | 43        |
| 30 | cAMP protects neutrophils against TNF- $\alpha$ -induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). <i>Journal of Leukocyte Biology</i> , 2004, 76, 641-647. | 1.5 | 41        |
| 31 | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015, 24, 3595-3607.   | 1.4 | 40        |
| 32 | Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. <i>Cancers</i> , 2021, 13, 5848.  | 1.7 | 40        |
| 33 | Annexin A2 as predictor biomarker of recurrent disease in endometrial cancer. <i>International Journal of Cancer</i> , 2015, 136, 1863-1873.   | 2.3 | 39        |
| 34 | Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 432.e1-432.e17.   | 0.7 | 38        |
| 35 | ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. <i>Oncotarget</i> , 2015, 6, 28440-28452.  | 0.8 | 37        |
| 36 | Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016, 105, 35-43.e10.  | 0.5 | 37        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. <i>Blood</i> , 2008, 111, 2866-2877.  | 0.6 | 35        |
| 38 | High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition. <i>Clinical Cancer Research</i> , 2013, 19, 2331-2341.                              | 3.2 | 35        |
| 39 | Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.  | 2.3 | 35        |
| 40 | Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. <i>Oncotarget</i> , 2014, 5, 1052-1061.                                  | 0.8 | 35        |
| 41 | Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer. <i>PLoS ONE</i> , 2014, 9, e90141.   | 1.1 | 34        |
| 42 | High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated. <i>PLoS ONE</i> , 2012, 7, e52795.   | 1.1 | 34        |
| 43 | Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0135220.  | 1.1 | 33        |
| 44 | Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. <i>Acta Radiologica</i> , 2018, 59, 1010-1017.                                   | 0.5 | 33        |
| 45 | High visceral fat percentage is associated with poor outcome in endometrial cancer. <i>Oncotarget</i> , 2017, 8, 105184-105195.   | 0.8 | 33        |
| 46 | Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 980-987.  | 1.1 | 32        |
| 47 | Patient-Derived Xenograft Models for Endometrial Cancer Research. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2431.  | 1.8 | 32        |
| 48 | High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 157, 260-267.   | 0.6 | 32        |
| 49 | Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. <i>Oncotarget</i> , 2016, 7, 69844-69856.   | 0.8 | 30        |
| 50 | Nostocyclopeptide-M1: A Potent, Nontoxic Inhibitor of the Hepatocyte Drug Transporters OATP1B3 and OATP1B1. <i>Molecular Pharmaceutics</i> , 2011, 8, 360-367.  | 2.3 | 29        |
| 51 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.            | 1.1 | 28        |
| 52 | High mRNA levels of 17 $\beta$ -hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 442, 51-57.                                  | 1.6 | 27        |
| 53 | Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 840-847. | 2.9 | 26        |
| 54 | Class I Phosphoinositide 3-Kinase PIK3CA/p110 $\alpha$ and PIK3CB/p110 $\beta$ Isoforms in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3931.                                       | 1.8 | 26        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. <i>PLoS Medicine</i> , 2020, 17, e1003111.   | 3.9 | 25        |
| 56 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .   | 0.3 | 25        |
| 57 | Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. <i>Gynecologic Oncology</i> , 2015, 137, 529-537.  | 0.6 | 24        |
| 58 | Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.  | 1.3 | 24        |
| 59 | Automated segmentation of endometrial cancer on MR images using deep learning. <i>Scientific Reports</i> , 2021, 11, 179.   | 1.6 | 24        |
| 60 | Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223.  | 1.1 | 22        |
| 61 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.  | 0.6 | 22        |
| 62 | The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2021, 109, 80-91.                   | 1.1 | 22        |
| 63 | Switch in FOXA1 Status Associates with Endometrial Cancer Progression. <i>PLoS ONE</i> , 2014, 9, e98069.   | 1.1 | 22        |
| 64 | Blocking 17 $\beta$ -hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. <i>Journal of Pathology</i> , 2018, 244, 203-214.   | 2.1 | 21        |
| 65 | Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1811-1823.  | 1.2 | 21        |
| 66 | Mitochondrial-Targeted Fatty Acid Analog Induces Apoptosis with Selective Loss of Mitochondrial Glutathione in Promyelocytic Leukemia Cells. <i>Chemistry and Biology</i> , 2003, 10, 609-618.  | 6.2 | 20        |
| 67 | Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. <i>Communications Medicine</i> , 2021, 1, .  | 1.9 | 20        |
| 68 | PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. <i>Scientific Reports</i> , 2017, 7, 10240.   | 1.6 | 19        |
| 69 | The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1393-1405.   | 1.0 | 18        |
| 70 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.  | 0.6 | 18        |
| 71 | Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. <i>Gynecologic Oncology</i> , 2018, 148, 197-203.  | 0.6 | 18        |
| 72 | Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. <i>Human Genetics</i> , 2021, 140, 1353-1365. | 1.8 | 18        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | <i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 334-345.                                | 3.2 | 17        |
| 74 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.               | 1.5 | 16        |
| 75 | Off-target effect of the Epac agonist 8-pCPT-2-O-Me-cAMP on P2Y12 receptors in blood platelets. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 603-608.                                     | 1.0 | 15        |
| 76 | Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.   | 0.6 | 15        |
| 77 | Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. <i>European Radiology</i> , 2020, 30, 2443-2453.                   | 2.3 | 15        |
| 78 | An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 538.  | 1.0 | 15        |
| 79 | A 10-gene prognostic signature points to <i>LIMCH1</i> and <i>HLA-DQB1</i> as important players in aggressive cervical cancer disease. <i>British Journal of Cancer</i> , 2021, 124, 1690-1698.                      | 2.9 | 15        |
| 80 | Endometrial cancer cells exhibit high expression of p110 $\beta$ and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. <i>Oncotarget</i> , 2017, 8, 3881-3894. | 0.8 | 15        |
| 81 | Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. <i>Gynecologic Oncology</i> , 2017, 147, 672-677.                   | 0.6 | 14        |
| 82 | Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 547.   | 1.1 | 14        |
| 83 | PI3K Pathway in Gynecologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e218-e221.                                  | 1.8 | 14        |
| 84 | MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer. <i>Insights Into Imaging</i> , 2022, 13, 1.   | 1.6 | 14        |
| 85 | A radiogenomics application for prognostic profiling of endometrial cancer. <i>Communications Biology</i> , 2021, 4, 1363.   | 2.0 | 14        |
| 86 | Blood steroids are associated with prognosis and fat distribution in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 152, 46-52.   | 0.6 | 13        |
| 87 | Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. <i>Cancers</i> , 2021, 13, 4551.   | 1.7 | 13        |
| 88 | Blood Metabolites Associate with Prognosis in Endometrial Cancer. <i>Metabolites</i> , 2019, 9, 302.   | 1.3 | 12        |
| 89 | Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. <i>Oncotarget</i> , 2017, 8, 109018-109026.       | 0.8 | 12        |
| 90 | Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. <i>PLoS ONE</i> , 2018, 13, e0206665.  | 1.1 | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 160, 396-404.  | 0.6 | 11        |
| 92  | Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 407.e1-407.e16.  | 0.7 | 11        |
| 93  | High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 373.   | 1.8 | 11        |
| 94  | The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. <i>European Journal of Hybrid Imaging</i> , 2018, 2, .   | 0.6 | 10        |
| 95  | Poor outcome in hypoxic endometrial carcinoma is related to vascular density. <i>British Journal of Cancer</i> , 2019, 120, 1037-1044.   | 2.9 | 10        |
| 96  | Incorporating molecular profiling into endometrial cancer management requires prospective studies. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 944-945.   | 1.2 | 10        |
| 97  | Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 370.  | 1.7 | 10        |
| 98  | Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2547.  | 1.8 | 9         |
| 99  | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.  | 1.1 | 9         |
| 100 | Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1695-1703.    | 1.1 | 9         |
| 101 | Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1014-1022.   | 2.9 | 9         |
| 102 | Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 90.e1-90.e20. | 0.7 | 9         |
| 103 | Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. <i>Oncotarget</i> , 2017, 8, 106989-107001.                        | 0.8 | 9         |
| 104 | Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. <i>Npj Genomic Medicine</i> , 2021, 6, 82.   | 1.7 | 9         |
| 105 | A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival. <i>Cancers</i> , 2021, 13, 5737.  | 1.7 | 9         |
| 106 | Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. <i>Cancers</i> , 2022, 14, 2372.   | 1.7 | 9         |
| 107 | Introduction of Aromatic Ring-Containing Substituents in Cyclic Nucleotides Is Associated with Inhibition of Toxin Uptake by the Hepatocyte Transporters OATP 1B1 and 1B3. <i>PLoS ONE</i> , 2014, 9, e94926.                                  | 1.1 | 8         |
| 108 | Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. <i>Gynecologic Oncology</i> , 2020, 156, 400-406.  | 0.6 | 8         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?. <i>Insights Into Imaging</i> , 2022, 13, .   | 1.6 | 8         |
| 110 | InÂvivo MR spectroscopy predicts high tumor grade in endometrial cancer. <i>Acta Radiologica</i> , 2018, 59, 497-505.   | 0.5 | 7         |
| 111 | Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. <i>PLoS ONE</i> , 2019, 14, e0210585.  | 1.1 | 7         |
| 112 | Nuclear upregulation of class I phosphoinositide 3-kinase p110 $\beta$ correlates with high 47S rRNA levels in cancer cells. <i>Journal of Cell Science</i> , 2021, 134, .  | 1.2 | 7         |
| 113 | Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. <i>Oncotarget</i> , 2017, 8, 68530-68541.   | 0.8 | 7         |
| 114 | Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. <i>Histopathology</i> , 2012, 60, 516-519.   | 1.6 | 5         |
| 115 | Type of vascular invasion in association with progress of endometrial cancer. <i>Apmis</i> , 2017, 125, 1084-1091.  | 0.9 | 5         |
| 116 | Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2019, 89, 90-98.           | 1.1 | 5         |
| 117 | Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy. <i>Cancers</i> , 2019, 11, 1885.  | 1.7 | 5         |
| 118 | Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 406.   | 1.8 | 5         |
| 119 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.  | 0.8 | 5         |
| 120 | Interobserver agreement and prognostic impact for MRI-based 2018 FIGO staging parameters in uterine cervical cancer. <i>European Radiology</i> , 2022, 32, 6444-6455.   | 2.3 | 5         |
| 121 | Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 256, 25-31. | 0.5 | 4         |
| 122 | Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. <i>Oncotarget</i> , 2017, 8, 9696-9707.  | 0.8 | 4         |
| 123 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.  | 1.8 | 3         |
| 124 | Preoperative pelvic MRI and 2-[18F]FDG PET/CT for lymph node staging and prognostication in endometrial cancerâ€”time to revisit current imaging guidelines?. <i>European Radiology</i> , 2023, 33, 221-232.                                    | 2.3 | 3         |
| 125 | Serine/Threonine Protein Phosphatases in Apoptosis. , 2006, , 151-166.  |     | 2         |
| 126 | Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. <i>Pathology Research and Practice</i> , 2014, 210, 774-778.   | 1.0 | 0         |



| #   | ARTICLE   | IF | CITATIONS |
|-----|---|----|-----------|
| 127 | Abstract 4169: Loss of GPR30 expression identifies estrogen receptor positive endometrial carcinoma patients with poor outcome. , 2011, , .                           |    | 0         |
| 128 | Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas.. , 2013, , .  |    | 0         |
| 129 | Abstract 2875: ATAD2 overexpression indentifies aggressive endometrial carcinomas. , 2014, , .  |    | 0         |
| 130 | Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer. , 2014, , .                           |    | 0         |
| 131 | Abstract 4731: High level of nuclear heat-shock factor 1 is associated with aggressive disease and suggests targets for therapy in endometrial carcinoma. , 2014, , . |    | 0         |
| 132 | Abstract LB-120: HER2 as a potential predictive marker and target for therapy in cervical cancer. , 2015, , .   |    | 0         |
| 133 | Abstract 1809: Expression of genes in the nuclear receptor superfamily defines a set of prognostic biomarkers in endometrial cancer. , 2018, , .                      |    | 0         |
| 134 | Abstract 4879: Poor outcome in hypoxic endometrial carcinoma is related to vascular density. , 2019, , .  |    | 0         |